Recent Research press releases & news

Presswire is the leading news platform where businesses, educational institutions, news reporters, etc. come together to share compelling news stories that transform opinions and impact lives. Presswire has an extensive media contact list for press releases, reaching millions of contacts. We ensure that your story lands on the right business desks and the right mass media outlets. To begin your press release distribution, send your stories to Presswire or by filling out the form here.

1

Detecting Multiple Diseases At Once: EU-Funded Didida Project Develops A Cost-Effective Mobile Based Solution In Africa

 

[PRESSWIRE] Nairobi - November 9, 2022 -- The Digital Innovations and Diagnostics for Infectious Diseases in Africa (Didida) had its official kick-off at the Strathmore University. Didida is an ambitious project to develop reliable, low-cost, mobile phone-connected tests to help detect multiple infectious diseases and non-communicable diseases (NCD) at once in sub-Saharan Africa. Didida also plans to invest in digital health infrastructure and train a new generation of African experts to meet the health needs of the continent.

1

World’s Leading AI Drone Learning Platform Launched with Free Access

 

[PRESSWIRE] London, UK - 30.09.22 -- COPTRZ Ltd, have launched their new drone learning experience platform (LXP) platform COPTRZ ACADEMY. COPTRZ claim that this is the leading platform of its type anywhere in the World.

1

CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2

 

[PRESSWIRE] Austria - 04.07.22 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent inhibitor of major variants of SARS- CoV-2 in the peer-reviewed journal Frontiers in Pharmacology (1).

1

NemaLife and UC Davis enter into a research partnership to test the therapeutic potential of several novel psychoplastogens developed in David E. Olson’s Lab

 

[PRESSWIRE] LUBBOCK, TX -- April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.

1

Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC

 

[PRESSWIRE] Vienna - 23rd February 2022 -- Eveliqure Biotechnologies GmbH, a clinical stage biotechnology company, today announces the publication of positive Phase I data with ShigETEC, its vaccine candidate against Shigellae and enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines10020340).

1

CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant

 

[PRESSWIRE] Austria - 10.12.21 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major respiratory viruses, such as SARS-CoV-2 and its variants, influenza and Respiratory Syncytial Virus (RSV).

1

EPILOG raises €1 million for international growth

Red Devil, Jan Vertonghen co-invests in Ghent-based scale-up to expand groundbreaking epilepsy AI technology to sleep and other neurological disorders...

CEBINA reports potency of azelastine against emerging dominant variants of SARS-CoV-2 in laboratory testing

 

[PRESSWIRE] Austria - 04 May, 2021 -- CEBINA GmbH, an Austrian biotech company, today announces that azelastine, previously identified as a potential anti-COVID-19 drug, is equally potent against newly emerging dominant variants of SARS-CoV-2 compared to the original virus. Azelastine is available as an anti-allergy nasal spray and is currently being tested in a Phase 2 efficacy trial for the treatment of early-stage COVID-19 disease.

1

Airionex Expands Executive Team to Support Historic Growth in Demand

[PRESSWIRE] SANTA ANA, January 26, 2021 -- Airionex, the leading global provider of bi-polar ionization air and surface purification technology, announced today that it has hired Françoise Parker as Senior Vice President of Sales and Marketing. Françoise will report to CEO Jukka Matikka, and will be responsible for sales team leadership, accelerating Airionex revenue throughout North America, the development and management of key channels, and overseeing the company’s marketing strategy.

1

Eveliqure announces the publication of key preclinical data for its clinical stage vaccine candidate against Shigellosis and ETEC

[PRESSWIRE] Austria - 19.11.20 -- Eveliqure Biotechnologies GmbH, a clinical-stage biotechnology company, today announces the publication of preclinical data with ShigETEC, its vaccine candidate against Shigellae and Enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines8040689).